Vertex Pharmaceuticals (VRTX) reported Q1 2026 revenue of $2.99 billion, exceeding market consensus, according to an SEC 8-K filing.
📊 Stock Price at Time of Report (May 6, 2026, 03:00 KST)
$421.57 ▼ -1.93%
Approximately ₩619,286 (Exchange rate: 1469)
Quarterly Results at a Glance
Vertex's Q1 revenue grew 8% year-over-year, driven by steady cystic fibrosis (CF) therapeutic sales. Growth was further supported by new product launches including sickle cell disease and acute pain treatments.
- Revenue: $2.99 billion, +8% YoY
- GAAP Net Income: $1.0 billion vs. $646 million in prior year
- Non-GAAP Adjusted Net Income: $1.1 billion, up $93 million YoY
- U.S. Revenue: $1.78 billion, +7% YoY
- International Revenue: $1.21 billion, +9% YoY
- Cash and Marketable Securities: $13.0 billion (as of March 31, 2026)
Full-Year Guidance
Vertex maintained its 2026 full-year revenue guidance at $12.95–$13.1 billion, with non-CF product revenues expected to exceed $500 million. CEO Reshma Kewalramani noted that growth from sickle cell disease, beta-thalassemia, and acute pain treatments drove over 25% of total growth, and the company is expanding into the renal disease space. Management expects tariff impacts to be minimal in 2026.
Market Reaction
Vertex shares declined following the earnings announcement. As of May 6, 2026, 03:00 KST, the stock traded at $421.57, down 1.93% from the prior close. Industry sources including StockStory and Yahoo Finance reported that both revenue and earnings exceeded consensus estimates. The maintenance of flat full-year guidance was cited as a key factor in the share price decline.
Key Pipeline Developments
Vertex completed a Biologics License Application (BLA) submission for povetacicept, a renal disease therapeutic candidate, requesting priority review for IgA nephropathy. The company also initiated clinical trials in primary membranous nephropathy and myasthenia gravis. The existing CF therapy ALYFTREK has now gained approvals across 8 regions including the U.S., UK, and EU. CASGEVY, the sickle cell and beta-thalassemia treatment, completed a U.S. BLA submission for pediatric patients ages 5 to under 12.
This article was auto-generated from the SEC 8-K filing and external news reports to provide timely dissemination of key financial data. Investors are advised to review official company disclosures before making trading decisions. Stock prices are as of report publication and may differ from current levels.
